Saltar apartados

Victor Meseguer


I obtained a major degree in Biology at the University of Murcia (2001). From early on I realised I was highly motivated for scientific research and I started working at the Francisca Sevilla Lab, in the ENCEBES- CSIC, where I was granted with a %u201CFundació Sèneca%u201D Fellowship. The results were published in The Experimental Journal of Botany (2006).

I did my PhD in Neurosciences at the Institut de Neurociencias d'Alacant under the supervision of Félix Viana. In order to fund my predoctoral work I obtained a %u201CMCYT%u201D fellowship at first, and a %u201C Generalitat Valenciana%u201D predoctoral fellowship afterwards. During my PhD I performed two scientific stays to learn %u201Cpatch-clamp%u201D and cell culture techniques at the KULeuven (Leuven, Belgium) for 3 months in 2004 and for 6 months in 2006. My thesis, presented in July 2009, obtained the Cum Laude rate and the Extraordinary PhD Award by the Universitat Miguel Hernández (UMH). I also presented my work in several international conferences and published 7 articles (with 2 first-author papers, one of them in The Journal of Neuroscience, one review, and I was co-author in prestigious journals such as Nature Neuroscience, The Journal of Neuroscience and The Journal of Physiology).

After obtaining the PhD degree, I did my first postdoc under the supervision of Carlos Belmonte (2010-2013). During that period of estafe I initiated and coordinated a project about the identification of TRPA1 as a direct molecular sensor of bacterial endotoxins on nociceptors. As result of that, I am co- inventor on a patent, concediu in 2013 and held by the UMH and CSIC, related to the use of TRPA1 antagonists for the treatment of symptoms caused by bacterial infections or bacterial endotoxins. Shortly after getting the patent approval, the results were published in Nature Communications (2014). Simultaneously, I was recognized by the UMH as Honorary Lecturer and participated in teaching Physiology subjects for Medicine students, and obtained in 2014 the positive evaluation by ANECA compulsory for recruitment by Public Universities of PhD assistant lecturers (Professor Ajudant Doctor) and) and PhD lecturers (Professor Contractat Doctor). After my first postdoc, seeking to expand my knowledge in the modulation of ió channel activity, and attracted by the highly competitive scientific environment and cutting-edge technology of the Department of Cellular and Molecular Biology of the University of Califòrnia at Berkeley, I moveu to Sant Francisco (USA) where I joined to Richard Kramer Group, a pioneer and world leader in the use of the sota-called %u201Cphotoswitches%u201D, small molecules that confer light sensitivity to ió channels. During this stay (2013-2015), I acquired first-hand experimental experience in photo-control of ió channels, and specifically I worked on the photo-modulation of retinal ganglion cells and HCN channels by DENAQ, a photoswitch that has been proven to be effective in the visual restoration in blind mice. The results allowed em to be coauthor in both Nature Neuroscience and Neuron in 2016. After that, I returned back to Carlos Belmonte and Juana Gallar lab, at the UMH, where I am leading two projects. On the one hand, we aim at defining corneal nerve plasticity in the adult living mouse. The first results have recently been presented in the SFN 2017. On the other hand, we llaure optically controlling corneal nerve activit by using photoswitches, and this work has been presented in EVER2017 and SENC2017.

Resum de Ponència: Restabliment de la funció visual mitjançant tècniques optofarmacológicas.

En els últims anys s'han desenvolupat estratègies optoquímicas per a regular l'activitat biològica de la retina. Aquest enfocament es basa en la modificació de fàrmacs, molècules amb activitat biològica i terapèutica, que els doten de foto- sensibilitat, i ha donat lloc a un nou camp de recerca denominat optofarmacología. L'optofarmacología es basa en l'ús de foto-commutadors moleculars (molecular photoswitches), que són molècules sintètiques que en ser il·luminades canvien la seua conformació isomérica i d'aquesta manera, són capaces d'unir-se a les seues proteïnes diana i modificar la seua activitat fisiològica. Entre els optofármacos, DENAQ ha sigut la molècula més prometedora fins avui, a causa que produeix el tret de senyals elèctrics depenents de llum en les cèl·lules ganglionares de ratolins cecs rd1/rd1. Així mateix, la injecció intravítrea de DENAQ en ratolins rd1/rd1 permet que els ratolins cecs siguen capaços d'associar l'estimulació de llum amb un estímul nociu en un paradigma d'aprenentatge. Per tot açò, els optofármacos es postulen com una eina prometedora per al tractament de pacients amb trastorns neurodegenerativos de la retina.


Universitat d'Alacant
Carretera Sant Vicent s/n
03690 Sant Vicent del Raspeig
Alacant (Spain)

Tel: (+34) 965 90 93 73

Fax: (+34) 965 90 93 69

Per a més informació:, i per a temes relacionats amb aquest servidor web:

Carretera de Sant Vicent del Raspeig, s/n - 03690 Sant Vicent del Raspeig - Alacant - Tel.: 96 590 3400 - Fax: 96 590 3464